Combination extended smoking cessation treatment plus home visits for smokers with schizophrenia: A randomized controlled trial

Nicotine and Tobacco Research

Volumn 19, Issue 1, 2017, Pages 68-76

  Brody, Arthur L ^a,b   Zorick, Todd ^a   Hubert, Robert ^a   Hellemann, Gerhard S ^a   Balali, Shabnam ^a   Kawasaki, Sarah S ^c   Garcia, Lizette Y ^a   Enoki, Ryutaro ^a   Abraham, Paul ^a   Young, Paulina ^a   McCreary, Charles ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Health Care for the Homeless ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE LOZENGE; NICOTINE PATCH; NICOTINE; NICOTINE GUM;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITIVE BEHAVIORAL THERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HOME VISIT; HUMAN; MALE; OUTCOME ASSESSMENT; PASSIVE SMOKING; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION; TREATMENT DURATION; AGED; COGNITIVE THERAPY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PREVENTION AND CONTROL; PROCEDURES; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGY; TOBACCO USE DISORDER;

ADULT; AGED; BUPROPION; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DIAGNOSIS, DUAL (PSYCHIATRY); HOUSE CALLS; HUMANS; MALE; MIDDLE AGED; NICOTINE; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER;

EID: 85014117593     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntw190     Document Type: Article

References (88)

1. Dickerson F, Stallings CR, Origoni AE, et al. Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999-2011. Psychiatr Serv. 2013;64(1):44-50.
2. Deleon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking - An Epidemiologic Survey in a State-Hospital. Am J Psychiatry. 1995;152(3):453-455.
3. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284(20):2606-2610.
4. Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172-1181.
5. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012;25(2):83-88.
6. Casey DA, Rodriguez M, Northcott C, Vickar G, Shihabuddin L. Schizophrenia: medical illness, mortality, and aging. Int J Psychiatry Med. 2011;41(3):245-251.
7. Steinberg ML, Williams JM, Ziedonis DM. Financial implications of cigarette smoking among individuals with schizophrenia. Tob Control. 2004;13(2):206.
8. Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs. 2013;27(12):1021-1048.
9. Lowe EJ, Ackman ML. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. Ann Pharmacother. 2010;44(4):727-732.
10. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15(6):469-494.
11. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007;64(18):1917-1921.
12. Fagerstrom K, Aubin HJ. Management of smoking cessation in patients with psychiatric disorders. Curr Med Res Opin. 2009;25(2):511-518.
13. Gershon Grand RB, Hwang S, Han J, George T, Brody AL. Short-term naturalistic treatment outcomes in cigarette smokers with substance abuse and/or mental illness. J Clin Psychiatry. 2007;68(6):892-898; quiz 980.
14. Etter M, Mohr S, Garin C, Etter JF. Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population. Schizophr Bull. 2004;30(2):459-468.
15. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507-2520.
16. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013;2:CD007253.
17. 2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care. 2008;53(9):1217-1222.
18. Tønnesen P. Smoking cessation: how compelling is the evidence? A review. Health Policy. 2009;91(suppl 1):S15-S25.
19. Fiore MC, Jaen CR, Baker TB. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: Department of Health and Human Services; 2008.
20. Abrams DB, Niaura RS, Brown RA, Emmons KM, Goldstein MG, Monti PM. The Tobacco Dependence Treatment Handbook: A Guide to Best Practices. New York, NY: The Guilford Press; 2003.
21. Fiore MC, Jaen CR, Baker TB. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services; 2008.
22. Gelkopf M, Noam S, Rudinski D, et al. Nonmedication smoking reduction program for inpatients with chronic schizophrenia: a randomized control design study. J Nerv Ment Dis. 2012;200(2):142-146.
23. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157(11):1835-1842.
24. George TP, Vessicchio JC, Sacco KA, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry. 2008;63(11):1092-1096.
25. Weiner E, Ball MP, Buchholz AS, et al. Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. J Clin Psychiatry. 2012;73(1):95-102.
26. Ruther T, Bobes J, De Hert M, et al. EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. Eur psychiatry. 2014;29(2):65-82.
27. Evins AE, Cather C. Effective cessation strategies for smokers with schizophrenia. Int Rev Neurobiol. 2015;124:133-147.
28. Tidey JW, Miller ME. Smoking cessation and reduction in people with chronic mental illness. BMJ. 2015;351:h4065.
29. Evins AE, Cather C, Laffer A. Treatment of tobacco use disorders in smokers with serious mental illness: toward clinical best practices. Harv Rev Psychiatry. 2015;23(2):90-98.
30. Lindsay RP, Tsoh JY, Sung HY, Max W. Secondhand smoke exposure and serum cotinine levels among current smokers in the USA. Tob Control. 2016;25(2):224-231.
31. Okoli CT, Browning S, Rayens MK, Hahn EJ. Secondhand tobacco smoke exposure, nicotine dependence, and smoking cessation. Public Health Nurs. 2008;25(1):46-56.
32. Eng L, Qiu X, Su J, et al. The role of second-hand smoke exposure on smoking cessation in non-tobacco-related cancers. Cancer. 2015;121(15):2655-2663.
33. Eng L, Su J, Qiu X, et al. Second-hand smoke as a predictor of smoking cessation among lung cancer survivors. J Clin Oncol. 2014;32(6):564-570.
34. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, NY: Biometrics Research, New York State Psychiatric Institute; 1998.
35. Westman EC, Behm FM, Simel DL, Rose JE. Smoking behavior on the first day of a quit attempt predicts long-term abstinence. Arch Intern Med. 1997;157(3):335-340.
36. Hymowitz N, Cummings KM, Hyland A, Lynn WR, Pechacek TF, Hartwell TD. Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tob Control. 1997;6(suppl 2):S57-S62.
37. Dale LC, Glover ED, Sachs DP, et al. Bupropion for smoking cessation: predictors of successful outcome. Chest. 2001;119(5):1357-1364.
38. Paluck EC, McCormack JP, Ensom MH, Levine M, Soon JA, Fielding DW. Outcomes of bupropion therapy for smoking cessation during routine clinical use. Ann Pharmacother. 2006;40(2):185-190.
39. Kozlowski LT, Porter CQ, Orleans CT, Pope MA, Heatherton T. Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HSI. Drug Alcohol Depend. 1994;34(3):211-216.
40. Batra A, Collins SE, Torchalla I, Schröter M, Buchkremer G. Multidimensional smoker profiles and their prediction of smoking following a pharmacobehavioral intervention. J Subst Abuse Treat. 2008;35(1):41-52.
41. Brody AL, Mukhin AG, Mamoun MS, et al. Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial. JAMA Psychiatry. 2014;71(7):797-805.
42. Brody AL, Mukhin AG, Shulenberger S, et al. Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density. Neuropsychopharmacology. 2013;38(8):1548-1556.
43. Brody AL, London ED, Olmstead RE, et al. Smoking-induced change in intrasynaptic dopamine concentration: effect of treatment for Tobacco Dependence. Psychiatry Res. 2010;183(3):218-224.
44. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Brit J Addict. 1991;86(9):1119-1127.
45. Fagerstrom KO. Measuring the degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978;3(3-4):235-241.
46. Prochaska JJ, Leek DN, Hall SE, Hall SM. Cognitive interviews for measurement evaluation of the Fagerström Test for Nicotine Dependence (FTND) in smokers with schizophrenia spectrum disorders. Addict Behav. 2007;32(4):793-802.
47. Steinberg ML, Williams JM, Steinberg HR, Krejci JA, Ziedonis DM. Applicability of the Fagerstrom Test for Nicotine Dependence in smokers with schizophrenia. Addict Behav. 2005;30(1):49-59.
48. Weinberger AH, Reutenauer EL, Allen TM, et al. Reliability of the Fagerström Test for Nicotine Dependence, Minnesota Nicotine Withdrawal Scale, and Tiffany Questionnaire for Smoking Urges in smokers with and without schizophrenia. Drug Alcohol Depend. 2007;86(2-3):278-282.
49. Allen MH, Debanne M, Lazignac C, Adam E, Dickinson LM, Damsa C. Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2011;168(4):395-399.
50. Chou KJ, Chen HK, Hung CH, Chen TT, Chen CM, Wu BJ. Readiness to quit as a predictor for outcomes of smoking-reduction programme with transdermal nicotine patch or bupropion in a sample of 308 patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2015;265(3):249-257.
51. Williams JM, Gandhi KK, Lu SE, Steinberg ML, Benowitz NL. Rapid smoking may not be aversive in schizophrenia. Nicotine Tob Res. 2013;15(1):262-266.
52. Wu BJ, Chen HK, Lee SM. Do atypical antipsychotics really enhance smoking reduction more than typical ones?: the effects of antipsychotics on smoking reduction in patients with schizophrenia. J Clin Psychopharmacol. 2013;33(3):319-328.
53. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-802.
54. Andreasen N. The Scale for Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa; 1983.
55. Guy W. Clinical Global Impression Scale. Rockville, MD: US Department of Health, Education, and Welfare; 1976.
56. Beck AT, Steer RA, Brown G. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
57. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277.
58. Guy W. Abnormal Involuntary Movement Scale. Washington, DC: US Department of Health, Education, and Welfare; 1976.
59. Griffith SD, Shiffman S, Heitjan DF. A method comparison study of timeline followback and ecological momentary assessment of daily cigarette consumption. Nicotine Tob Res. 2009;11(11):1368-1373.
60. Toll BA, Cooney NL, McKee SA, O'Malley SS. Do daily interactive voice response reports of smoking behavior correspond with retrospective reports? Psychol Addict Behav. 2005;19(3):291-295.
61. Toll BA, Cooney NL, McKee SA, O'Malley SS. Correspondence between Interactive Voice Response (IVR) and Timeline Followback (TLFB) reports of drinking behavior. Addict Behav. 2006;31(4):726-731.
62. Zorick T, Mandelkern MA, Brody AL. A naturalistic study of the association between antidepressant treatment and outcome of smoking cessation treatment. J Clin Psychiatry. 2014;75(12):e1433-e1438.
63. Carmody TP. Preventing relapse in the treatment of nicotine addiction: current issues and future directions. J Psychoactive Drugs. 1990;22(2):211-238.
64. Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD U.S. Department of Health and Human Services. Public Health Service; 2000.
65. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003;5(1):13-25.
66. Perkins KA, Karelitz JL, Jao NC. Optimal carbon monoxide criteria to confirm 24-hr smoking abstinence. Nicotine Tob Res. 2013;15(5):978-982.
67. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustainedrelease bupropion and placebo for smoking cessation. N Engl J Med. 1997;337(17):1195-1202.
68. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav. 2009;92(1):6-11.
69. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustainedrelease bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340(9):685-691.
70. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 2005;100(3):299-303.
71. Rigotti NA, Gonzales D, Dale LC, Lawrence D, Chang Y. A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction. 2009;104(2):266-276.
72. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry. 2005;187(4):366-371.
73. Levine SZ, Leucht S. Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms. Schizophr Res. 2013;145(1-3):125-127.
74. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28-37.
75. Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebocontrolled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007;27(4):380-386.
76. Dale Horst W, Klein MW, Williams D, Werder SF. Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia. Neuropsychiatr Dis Treat. 2005;1(4):349-355.
77. Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA. 2014;311(2):145-154.
78. Cather C, Dyer MA, Burrell HA, Hoeppner B, Goff DC, Evins AE. An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia. Journal of dual diagnosis. 2013;9(1):87-93.
79. Lutenbacher M, Gabbe PT, Karp SM, et al. Does additional prenatal care in the home improve birth outcomes for women with a prior preterm delivery? A randomized clinical trial. Matern Child Health J. 2014;18(5):1142-1154.
80. Windsor R, Clark J, Cleary S, et al. Effectiveness of the Smoking Cessation and Reduction in Pregnancy Treatment (SCRIPT) dissemination project: a science to prenatal care practice partnership. Matern Child Health J. 2014;18(1):180-190.
81. French GM, Groner JA, Wewers ME, Ahijevych K. Staying smoke free: an intervention to prevent postpartum relapse. Nicotine Tob Res. 2007;9(6):663-670.
82. Lepore SJ, Winickoff JP, Moughan B, et al. Kids Safe and Smokefree (KiSS): a randomized controlled trial of a multilevel intervention to reduce secondhand tobacco smoke exposure in children. BMC Public Health. 2013;13:792.
83. Montaudié-Dumas I, Giovannini-Chami L, Debai C, et al. [Impact on the indoor environment of allergic children of the medical counselor on indoor environment, after two successive visits at 6 months interval]. Arch Pediatr. 2013;20(12):1288-1295.
84. Baker TB, Piper ME, Stein JH, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: a Randomized Clinical Trial. JAMA. 2016;315(4):371-379.
85. Schnoll RA, Goelz PM, Veluz-Wilkins A, et al. Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Inter Med. 2015;175(4):504-511.
86. Chengappa KN, Perkins KA, Brar JS, et al. Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(7):765-772.
87. Stanton CA, Papandonatos GD, Shuter J, et al. Outcomes of a tailored intervention for cigarette smoking cessation among Latinos living with HIV/AIDS. Nicotine Tob Res. 2015;17(8): 975-982.
88. Jarvis MJ, Tunstall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y. Comparison of tests used to distinguish smokers from nonsmokers. Am J Public Health. 1987;77(11):1435-1438.